Related Experiment Video
Updated: Jun 12, 2026

Pseudofracture: An Acute Peripheral Tissue Trauma Model
Published on: April 18, 2011
Association of early interleukin-6 level with injury severity and mortality in trauma patients: Systematic review and
Ibrahim Al-Hassani1, Ayman El-Menyar2,3, Mashhood Naduvilekandy4
1Medical College, Weill Cornell Medicine, Doha 24144, Qatar.
Background:
Polytrauma is associated with the release of various biomarkers, including interleukin (IL)-6, a proinflammatory cytokine with prognostic value.
Aim:
To evaluate the association between IL-6 measured within the first 24 hours of admission and the injury severity score (ISS) among adult polytrauma patients and to explore the link between early IL-6 levels and in-hospital mortality.
Methods:
We conducted a systematic review and meta-analysis of articles published between 2004 and 2024 in the OVID EMBASE and PubMed databases. The primary outcomes of interest were ISS and all-cause in-hospital mortality. Heterogeneity among the included studies was assessed using the I² statistic. Correlations were performed using Pearson's or Spearman's correlation coefficients. The Newcastle-Ottawa Scale was used to assess bias in the included studies.
Results:
A total of 1126 studies were screened, of which 15 were selected, yielding 2106 polytrauma patients. The pooled effect size for the correlation between IL-6 and ISS using the Pearson's coefficient was 0.49 [95%CI: 0.36-0.60; I²: 72.2%, P (heterogeneity) = 0.02], while that for studies using the Spearman's coefficient was 0.50 [95%CI: 0.41-0.58; I²: 33.2%, P (heterogeneity) = 0.18]. Six studies indicated that IL-6 levels were significantly elevated in non-survivors compared with survivors.
Conclusion:
Among polytrauma patients, elevated IL-6 levels within the first 24 hours of admission are associated with higher rates of severe injury and in-hospital mortality. Future research should investigate how early IL-6 levels can be used with other biomarkers to predict injury severity and worse outcomes. Additionally, larger-scale studies should be conducted to assess the tool's validity across a variety of populations.
